1. Home
  2. RCKT vs FPH Comparison

RCKT vs FPH Comparison

Compare RCKT & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • FPH
  • Stock Information
  • Founded
  • RCKT 1999
  • FPH 2009
  • Country
  • RCKT United States
  • FPH United States
  • Employees
  • RCKT N/A
  • FPH N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • FPH Real Estate
  • Sector
  • RCKT Health Care
  • FPH Finance
  • Exchange
  • RCKT Nasdaq
  • FPH Nasdaq
  • Market Cap
  • RCKT 328.6M
  • FPH 390.0M
  • IPO Year
  • RCKT N/A
  • FPH 2017
  • Fundamental
  • Price
  • RCKT $3.28
  • FPH $5.68
  • Analyst Decision
  • RCKT Buy
  • FPH
  • Analyst Count
  • RCKT 13
  • FPH 0
  • Target Price
  • RCKT $12.96
  • FPH N/A
  • AVG Volume (30 Days)
  • RCKT 6.0M
  • FPH 150.3K
  • Earning Date
  • RCKT 08-07-2025
  • FPH 10-16-2025
  • Dividend Yield
  • RCKT N/A
  • FPH N/A
  • EPS Growth
  • RCKT N/A
  • FPH 46.82
  • EPS
  • RCKT N/A
  • FPH 1.08
  • Revenue
  • RCKT N/A
  • FPH $197,429,000.00
  • Revenue This Year
  • RCKT N/A
  • FPH N/A
  • Revenue Next Year
  • RCKT $108.43
  • FPH N/A
  • P/E Ratio
  • RCKT N/A
  • FPH $5.28
  • Revenue Growth
  • RCKT N/A
  • FPH N/A
  • 52 Week Low
  • RCKT $2.19
  • FPH $3.10
  • 52 Week High
  • RCKT $22.01
  • FPH $6.71
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 51.17
  • FPH 56.60
  • Support Level
  • RCKT $2.88
  • FPH $5.51
  • Resistance Level
  • RCKT $3.74
  • FPH $5.77
  • Average True Range (ATR)
  • RCKT 0.27
  • FPH 0.14
  • MACD
  • RCKT 0.02
  • FPH 0.04
  • Stochastic Oscillator
  • RCKT 35.43
  • FPH 95.83

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: